MicroRNA profiles classify papillary renal cell carcinoma subtypes

Background:Besides the conventional clear-cell renal cell carcinoma (ccRCC), papillary RCC (pRCC) is the second most common renal malignancy. Papillary RCCs can further be subdivided into two distinct subtypes. Although a clinical relevance of pRCC subtyping has been shown, little is known about the molecular characteristics of both pRCC subtypes.Methods:We performed microarray-based microRNA (miRNA) expression profiling of primary ccRCC and pRCC cases. A subset of miRNAs was identified and used to establish a classification model for ccRCC, pRCC types 1 and 2 and normal tissue. Furthermore, we performed gene set enrichment analysis with the predicted miRNA target genes.Results:Only five miRNAs (miR-145, -200c, -210, -502-3p and let-7c) were sufficient to identify the samples with high accuracy. In a collection of 111 tissue samples, 73.9% were classified correctly. An enrichment of miRNA target genes in the family of multidrug-resistance proteins was noted in all tumours. Several components of the Jak-STAT signalling pathway might be targets for miRNAs that define pRCC tumour subtypes.Conclusion:MicroRNAs are able to accurately classify RCC samples. Deregulated miRNAs might contribute to the high chemotherapy resistance of RCC. Furthermore, our results indicate that pRCC type 2 tumours could be dependent on oncogenic MYC signalling.

[1]  Zhe-Sheng Chen,et al.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases , 2011, The FEBS journal.

[2]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[3]  George M Yousef,et al.  Accurate molecular classification of kidney cancer subtypes using microRNA signature. , 2011, European urology.

[4]  Heng Tao Shen,et al.  Principal Component Analysis , 2009, Encyclopedia of Biometrics.

[5]  P. Lara,et al.  Renal cell carcinoma: current status and emerging therapies. , 2007, Cancer treatment reviews.

[6]  J. Steitz,et al.  Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR , 2007, Proceedings of the National Academy of Sciences.

[7]  Jörg Grigull,et al.  miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. , 2011, The Journal of urology.

[8]  C. Bracken,et al.  The role of microRNAs in metastasis and epithelial-mesenchymal transition , 2009, Cellular and Molecular Life Sciences.

[9]  A. Disch,et al.  Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. , 2011, Analytical biochemistry.

[10]  P. Choyke,et al.  Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. , 1999, The American journal of pathology.

[11]  Christina Backes,et al.  Toward the blood-borne miRNome of human diseases , 2011, Nature Methods.

[12]  Bin Tean Teh,et al.  MicroRNA profiling of human kidney cancer subtypes. , 2009, International journal of oncology.

[13]  A. Evans,et al.  miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215 , 2011, British Journal of Cancer.

[14]  Xin Huang,et al.  MiR-210--micromanager of the hypoxia pathway. , 2010, Trends in molecular medicine.

[15]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[16]  Arif B Ekici,et al.  MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening , 2012, International journal of cancer.

[17]  Michael A. S. Jewett,et al.  The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. , 2012, Journal of Molecular Diagnostics.

[18]  Hailong Wu,et al.  p53 represses c-Myc through induction of the tumor suppressor miR-145 , 2009, Proceedings of the National Academy of Sciences.

[19]  Ricky T. Tong,et al.  Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. , 2009, Molecular cell.

[20]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[21]  Bin Tean Teh,et al.  A molecular classification of papillary renal cell carcinoma. , 2005, Cancer research.

[22]  B. Delahunt,et al.  Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[23]  H. Kung,et al.  MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells* , 2011, The Journal of Biological Chemistry.

[24]  Wei Guo,et al.  Identification of miRs-143 and -145 that Is Associated with Bone Metastasis of Prostate Cancer and Involved in the Regulation of EMT , 2011, PloS one.

[25]  C. Elie,et al.  Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. , 2007, Urology.

[26]  Gunter Meister,et al.  miRNAs Get an Early Start on Translational Silencing , 2007, Cell.

[27]  W. Linehan,et al.  Intrinsic drug resistance in primary and metastatic renal cell carcinoma. , 1999, The Journal of urology.

[28]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[29]  L. Thomas,et al.  Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma , 2011, Journal of Medical Genetics.

[30]  Ximing J. Yang,et al.  Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. , 2007, Cancer research.

[31]  G. Bhanot,et al.  Identification of a microRNA panel for clear-cell kidney cancer. , 2010, Urology.

[32]  Jelle J. Goeman,et al.  Genome-Wide MicroRNA Expression Analysis of Clear Cell Renal Cell Carcinoma by Next Generation Deep Sequencing , 2012, PloS one.

[33]  Christina Backes,et al.  GeneTrail—advanced gene set enrichment analysis , 2007, Nucleic Acids Res..

[34]  L. O’Driscoll,et al.  Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma , 2009, BMC urology.

[35]  A. Poprach,et al.  Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients , 2012, Genes, chromosomes & cancer.

[36]  M. F. Shannon,et al.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. , 2008, Cancer research.

[37]  Hans Lehrach,et al.  MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy , 2009, Journal of cellular and molecular medicine.

[38]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.